rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Unicycive Therapeutics, Inc.

UNCY · Nasdaq

Health CareBiotechnologyNot moving yet

UNCY stood above a rising 150-day average in 22 of the last 52 weekly readings, and has been out of that trend for the last 16 weeks. It is 45.0% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 16
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
78 (+29)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 22 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders78+29 on the quarter
New · exited35 · 6
Reported value$54.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20261,413,381$6.6M+1,377,478+3836.7%
Nantahala Capital Management, LLCadded · filed 14 Aug 20261,401,447$6.6M+462,245+49.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,071,481$5.0M+260,051+32.0%
Octagon Capital Advisors LPunchanged · filed 14 Aug 20261,000,000$4.7M00.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026564,019$2.6M+360,275+176.8%
Vivo Capital, LLCreduced · filed 14 Aug 2026550,000$2.6M-1,239,916−69.3%
MARSHALL WACE, LLPadded · filed 13 Aug 2026547,862$2.6M+392,924+253.6%
Logos Global Management LPunchanged · filed 14 Aug 2026473,563$2.2M00.0%
STATE STREET CORPadded · filed 7 Aug 2026450,162$2.1M+370,135+462.5%
Diametric Capital, LPadded · filed 14 Aug 2026374,132$1.8M+293,770+365.6%
31 Mar 2023 – 30 Jun 2026
144576Mar 23Dec 23Dec 24Sep 25Jun 26

News

Everyone who traded it

Douglas Jermasek Company insiderEVP, Corporate Strategy · last 14 May 20260 · 0
John Townsend Company insiderCFO · last 14 May 20260 · 0
Pramod Gupta Company insiderEVP, Pharmaceuticals and BD · last 14 May 20260 · 0
Sandeep Laumas Company insiderDirector · last 14 May 20260 · 0
Sara Kenkare-Mitra Company insiderDirector · last 14 May 20260 · 0
Shalabh K. Gupta Company insiderCEO · last 14 May 20260 · 0
Gaurav Aggarwal Company insiderDirector · last 25 Aug 20250 · 0
John L. Ryan Company insiderDirector · last 5 Sep 20230 · 0
Brigitte Schiller Company insiderDirector · last 15 Jul 20221 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-97.7%
Share count trendFY 2025 · to 30 Mar 202614.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$29.2M
Free cash flowFY 2025 · to 31 Dec 2025−$31.3M

Analyst forecasts

No analyst forecasts yet.